Group psilocybin therapy appears feasible and well tolerated among low-income adults with depression, according to a small study conducted within Oregon’s state-regulated psilocybin program. Participants’ depression scores dropped substantially after two group dosing sessions, though the study had no comparison group, so the role of psilocybin itself remains uncertain. The findings were published in the Journal of Psychedelic Studies. Psilocybin is the primary psychoactive compound found in certain species of fungi, often known as “magic mushrooms.” Under supervision, it is consumed to induce an altered state of consciousness that can help people process difficult emotions. Major depressive disorder is a common mental health condition characterized by persistent feelings of sadness, fatigue, and a loss of interest in daily activities. Interest in psilocybin as a depression treatment has grown rapidly. For example, a 2020 randomized clinical trial found that psilocybin, paired with psychotherapy, produced rapid and substantial reductions in depression. But the people taking part in this research have tended to be better off than average: a 2025 systematic review found that only about 1 in …